Abstract: Disclosed are compounds and methods for treating tauopathy.

Abstract: The present disclosure relates to methods of treating coronavirus diseases comprising conjointly administering a combination of a PLpro inhibitor and an Mpro inhibitor, and to associated compositions.

Abstract: Degradable hollow shell particles are disclosed that can encapsulate cells within the hollow inner cavity that allows for the high-throughput screening and sorting of the encapsulated cells based on their phenotypic properties. The solid-phase of the particle is porous such that solution exchange can occur between the external environment and the interior cavity. Further, the solid-phase contains degradable crosslinkers and can be degraded to release enclosed biological entities. An example embodiment consists of encapsulating a cell within the hollow shell particle, allowing the cell to accumulate biomass, selecting hollow shell particles based on accumulated biomass, and degrading the hollow shell particles to release the cells and develop hyper-producing cell lines. Exemplary cell types include microalgae, mammalian cells, bacteria, yeast, and fungi.

Abstract: This disclosure relates to methods of treating viral infections, such as influenza or coronavirus, with certain inhibitors, such as kinase inhibitors.

Abstract: Disclosed herein are methods of treating a disease or disorder characterized by an increased secretion of adrenocorticotropic hormone (e.g., Cushing's disease). Also disclosed herein are methods of identifying compounds for use in treating said diseases or disorders.

Abstract: This disclosure relates to methods of treating cancer (e.g., melanoma) with (MI-181).

Abstract: The invention provides a sensitive cell-based assay, in which stably expressed mutant Huntingtin (mHTT) fragments serve as biosensors to detect mHTT species present in biosamples or can be used to identify novel compounds for use as therapeutics for the treatment of HD.

Abstract: Disclosed herein inter alia are compositions and methods useful in the treatment of infectious diseases and exposure to toxins.

Abstract: This disclosure relates to antimitotic compounds, compositions comprising therapeutically effective amounts of these compounds, and methods of using those compounds and compositions in treating hyperproliferative disorders, e.g., cancers and myelodysplastic syndromes.

Abstract: This disclosure relates to antimitotic compounds, compositions comprising therapeutically effective amounts of these compounds, and methods of using those compounds and compositions in treating hyperproliferative disorders, e.g., cancers and myelodysplastic syndromes.

Abstract: Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided.

Abstract: Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided.

Abstract: Disclosed herein inter alia are compositions and methods useful in the treatment of infectious diseases and exposure to toxins.

Abstract: Embodiments of the present invention provide compounds and compositions thereof, which are effective for mitigating tissue damage or lethality induced by an agent, and methods of making and using the same.

Abstract: Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided.

Abstract: Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided.

Abstract: Embodiments of the present invention provide compounds and compositions thereof, which are effective for mitigating tissue damage or lethality induced by an agent, and methods of making and using the same.

Abstract: The present invention provides, inter alia, fluorogenic enzyme substrates, such as fluorogenic polypeptide substrates, libraries of fluorogenic enzyme substrates and methods for assaying for enzymatically active enzymes, such as hydrolases (e.g., proteases), in biological samples.

Abstract: Method for preparing rhodamine on a solid support and, in particular, methods for the economical preparation of rhodamine NHS ester are disclosed.